Prescription drug abuse is a serious public health concern that has been exacerbated by the stress of living through the COVID-19 pandemic. Behind this troubling trend are individual people, each with their own story to share.

Altasciences recently launched a podcast series, The Many Faces of Recreational Drug Use, to provide insight into the personal experiences of individuals who abuse opioids and stimulants. Hosted by Altasciences’ Chief Scientific Officer, Dr. Beatrice Setnik, with expert commentary by Psychiatrist and Senior Principal Investigator, Dr. Debra Kelsh, the first episode provides a candid discussion of some of the hopes and challenges experienced by those who struggle with drug abuse.

See the first episode.

Speak with an expert about your research needs.

You may also be interested in the following:

• Webpage: Human Abuse Potential
• Webinar: Navigating Early Phase CNS-Active Drug Development
• The Altascientist: CNS-Active Drugs – Complex Considerations

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Choosing the Right Partner for Your Formulation Needs

Altasciences’ extensive formulation and manufacturing services, integrated with our early phase drug development offering, spans across the full drug development pathway, from discovery through commercialization. Our scientists have decades of expertise with both simple and complex dosage forms, and a successful track record of formulating molecules and developing the drug products required to support early phase clinical trials.
 
Discover our full range of analytical services, including: 

• Drug product release and stability testing
• Method development, qualification, and validation 
• On-site, ICH stability storage and testing

Get a head start on your project ― speak with one of our scientists.
 
You may also be interested in the following:

• Webpage: Pharmaceutical Contract Manufacturing Services
• Webinar: Overcoming the Challenges of Manufacturing and Clinical Trials
• Webpage: Clinical Trial Services

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

The thorough and precise evaluation of cardiac effects is a critical element of new chemical entity development. You can choose to add early cardiac safety assessment to your first-in-human studies, or wait and perform a Thorough QT prolongation study; either way, we can help you with the study design and conduct.

In this educational video, Dr. Beatrice Setnik, Altasciences’ Chief Scientific Officer, walks you through the differences between early and late QT prolongation testing.

Watch the video.

Speak with our experts today for help in deciding between early and late QT prolongation testing.  

You may also be interested in the following: 

• Webpage: QT Assessment
• Fact Sheets:
  • Safety Pharmacology
  • Cardiac Assessment 
  • First-in-Human
• The Altascientist: Cardiac Clinical Trials, Global Regulatory Requirements, Design, and Timing of QT Assessment (Case Study Included)

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.

Investigating the Abuse Potential of your CNS-Active Therapeutic

The FDA Guidance, Assessment of Abuse Potential of Drugs, states: 

Drug products with abuse potential generally contain drug substances that have central nervous system (CNS) activity and produce euphoria (or other changes in mood), hallucinations, and effects consistent with CNS depressants or stimulants. Thus, if a drug substance is CNS-active, the new drug product containing that drug substance will likely need to undergo a thorough assessment of its abuse potential…

The results of a human abuse potential (HAP) trial can indicate that your product will need an abuse-deterrent formulation (ADF), or specific labelling. Altasciences’ scientific, regulatory, and clinical experts will work with you to design a roadmap for your HAP evaluation program. 

HAP trials are procedurally intense, requiring high levels of skill and experience, secure clinical facilities with the necessary licenses, and pharmacy capabilities and expertise to ensure appropriate handling and storage of the drug products. 

For a more in-depth look at the requirements and implications of HAP trials for your drug development program, consult The Altascientist — Assessing Human Abuse Potential to Limit the Misuse and Abuse of Prescription Drugs.

Speak with an expert today for more information or to review your specific program requirements.


Related Resources:

Webinar: To Control or be Controlled – Navigating the Abuse Potential Evaluation of CNS-Active Drugs for EU and US Submissions

Scientific Poster: Identifying Appropriate Outcome Measures and Methodology to Evaluate the Abuse, Misuse, Dependence, and Impairing Effects of CNS-Active Drugs in Healthy Volunteer and Patient Trials

Webpage: Human Abuse Potential


Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

On-Time Delivery

Over the last 12 months, our project management team has played a key role in achieving a 99% on-time delivery success rate on your primary KPIs.

Altasciences’ high-quality project management is key to the success of your drug development programs, and is an integral part of our service offering. Our project management team has extensive expertise in managing studies for a wide range of therapeutic areas in small and large molecules, and will oversee every aspect of your study.

Partner with us to ensure seamless and timely communication for the successful completion of your project.

Contact us

You may also be interested in the following:

Webpages:

• Full-Time Equivalent Capabilities
• Tell Us Once™
• Clinical Trial Services

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Altasciences’ offers scalable flow cytometry solutions, and leverages extensive knowledge to help ensure a smooth transition from preclinical to clinical studies. We provide you with:

• Dedicated flow cytometry scientists available to you early in the process to help determine the most appropriate strategy for non-GLP, GLP, and GCP testing
• Extensive knowledge with exploratory and GLP studies from panel development to validation
• Design and development of receptor occupancy (RO) assays
• Strategically located laboratories in both the U.S. and Canada.
• State-of-the-art instrumentation
• Rapid turnaround between sample collection and analysis

Altasciences has the same instrumentation in its U.S. preclinical site and Canadian site, which allows assay transfer for easy transition from preclinical to clinical studies.

Download flow cytometry fact sheet

Speak to a flow scientist for guidance on your assay development or validation strategy.

You may also be interested in the following:

• Webpage: Therapeutic Areas of Clinical Research
• Fact Sheet: First-in-Human Trials Capabilities
• The Altascientist: Facing Bioanalytical Challenges

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.